MedTrace Logo

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

NCT07365410 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-26

No results posted yet for this study

Summary

This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effective and safer.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Brain Metastases
  • Furmonertinib
  • EGFR Mutation

Interventions

DRUG

Furmonertinib

Oral administration, 160mg once daily.

DRUG

Furmonertinib

Oral administration, 80mg once daily

DRUG

carboplatin

Intravenous infusion, cycle-based (per study protocol).

DRUG

pemetrexed

Intravenous infusion, cycle-based (per study protocol).

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-05-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365410 on ClinicalTrials.gov